MétaCan
Menu
← Back to cohort
Record W4412748875 · doi:10.1371/journal.pone.0329299

Comparative effectiveness and safety of insulin reference biologics versus biosimilars for types 1 and 2 diabetes mellitus: Protocol for a systematic review of real-world studies

2025· review· en· W4412748875 on OpenAlexaff
Martin Ho, Araniy Santhireswaran, Tara Gomes, Muhammad Mamdani, Mina Tadrous

Bibliographic record

VenuePLoS ONE · 2025
Typereview
Languageen
FieldMedicine
TopicDiabetes Management and Research
Canadian institutionsSt. Michael's HospitalWomen's College HospitalUniversity of Toronto
Fundersnot available
KeywordsMedicineBiosimilarRandomized controlled trialType 2 Diabetes MellitusHypoglycemiaGlycated hemoglobinObservational studyIntensive care medicineSystematic reviewType 1 diabetesDiabetic ketoacidosisDiabetes mellitusMEDLINEType 2 diabetesInsulinInternal medicineEndocrinology

Abstract

fetched live from OpenAlex

INTRODUCTION: Diabetes mellitus is characterized by insulin deficiency or resistance. The two main types of diabetes mellitus are type 1 (T1DM) and type 2 (T2DM). Insulin is the mainstay of therapy for T1DM and often the last-line therapy for T2DM. Biosimilar insulins are cost-saving alternatives to reference products that may improve access for patients and sustainability for healthcare systems. Despite supporting evidence from randomized controlled trials, biosimilar insulin uptake is poor, and real-world evidence of their safety and effectiveness is limited. OBJECTIVE: Our objective is to compare the real-world effectiveness and safety of insulin biosimilars versus reference products in adults with diabetes mellitus. ELIGIBILITY CRITERIA: We will include observational studies and open-label pragmatic randomized controlled trials. We will exclude other randomized controlled trials, literature reviews, meta-analyses, case series, case reports, study protocols, opinion pieces, and conference abstracts. Our primary effectiveness outcome will be glycated hemoglobin (HbA1c) and our primary safety outcome will be hypoglycemia. Our secondary outcomes will include fasting plasma glucose; time in range; microvascular complications; health-related quality of life; physician visits, emergency department visits, and hospital admissions for hypoglycemia, hyperglycemia, and diabetic ketoacidosis; weight gain; immunogenicity; injection site reactions; and incident cancers. METHODS: The search strategy combines three key concepts: diabetes, insulin, and biosimilars. We will conduct a structured search in MEDLINE, EMBASE, and International Pharmaceutical Abstracts. We will also search in grey literature databases, targeted websites, and the Google search engine. Finally, we will scan forward and backward citations. Articles will be screened, extracted, and appraised independently by two reviewers. Data will be descriptively summarized. DISCUSSION: Our systematic review of the real-world evidence on biosimilar insulins can help support clinical and policy decisions that impact the care of patients with T1DM or T2DM.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.069
metaresearch head score (Gemma)0.107
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.069
Threshold uncertainty score0.367

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0690.107
Meta-epidemiology (narrow)0.0070.004
Meta-epidemiology (broad)0.0290.028
Bibliometrics0.0150.016
Science and technology studies0.0030.004
Scholarly communication0.0080.007
Open science0.0050.006
Research integrity0.0080.005
Insufficient payload (model declined to judge)0.0340.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.291
GPT teacher head0.467
Teacher spread0.176 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuePLoS ONE→Same topicDiabetes Management and Research→French-language works237,207→